Entry Detail



General Information

Database ID:exR0087885
RNA Name:hsa-miR-200a-3p
RNA Type:miRNA
Chromosome:chr1
Starnd:+
Coordinate:
Start Site(bp):1167916End Site(bp):1167937
External Links:hsa-miR-200a-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ANP32E
chr1
150218417
150236156
-
ARPC5
chr1
183620846
183635783
-
GALNT10
chr5
154190730
154420984
+
KRT10
chr17
40818117
40822614
-
PDHA1
chrX
19343893
19361718
+
PIGW
chr17
36534987
36539310
+
QKI
chr6
163414000
163578592
+
QSER1
chr11
32892820
32993316
+
RMND5A
chr2
86720291
86778041
+
TNRC6B
chr22
40044817
40335808
+
C6orf62
chr6
24704861
24719998
-
PLAG1
chr8
56160909
56211324
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001329
chr3
119219541
119222868
+
hsa_circ_0001376
chr3
194169185
194175121
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC016831.1
chr7
130876809
130913310
-
AC023509.1
chr12
53441741
53467528
+
AC234582.1
chr1
155195004
155205495
+
AL049840.4
chr14
103694516
103695050
-
MALAT1
chr11
65497688
65506516
+
MIR29B2CHG
chr1
207801518
207879115
-
NEAT1
chr11
65422774
65445540
+
OIP5-AS1
chr15
41283990
41309737
+
PINK1-AS
chr1
20642657
20652193
-
SNHG15
chr7
44983023
44986961
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.